Apidra fda approval 2004?

Yes. Apidra (insulin glulisine) was approved by the U.S. FDA in 2004 (in November 2004, to be exact).

What it is:
- A rapid-acting insulin analog used to improve glycemic control in adults and children with type 1 or type 2 diabetes.
- Used subcutaneously, often in combination with a longer-acting insulin, or in insulin pumps.

How it works (general):
- Fast-acting: starts to work within about 15 minutes after injection, with peak effect around 1 hour, and a duration of several hours (roughly 3–5 hours, depending on individual factors).

Safety notes (high-level):
- Commonly causes hypoglycemia if meals are skipped or if dosing is incorrect.
- Stored and handled per the product labeling.
- Any dose adjustments should be guided by a healthcare provider.

If you’d like, I can look up the exact FDA press release date or provide the official FDA label information.